This fourth volume in the series Advances in Vision Research describes importance advancements in basics to translational research, including new therapeutics for genetic eye diseases. Recent US FDA approval of the first gene therapy for an inherited retinal disease, due to a mutation in the RPE65 gene, has led to an upsurge in translational eye research. The coverage in this volume includes corneal diseases, myopia, cataract, glaucoma, inherited retinal diseases, inherited optic neuropathy, and other genetic eye diseases. New developments such as the application of artificial intelligence in translational eye research are also discussed. All chapters are written by leading researchers working on eye genetics from the fields of Human Genetics, Ophthalmology, Molecular Biology, Biochemistry, Sensory Sciences, and Clinical Research. Advances in Vision Research, Volume IV will be a major resource for all researchers, clinicians, clinical researchers, and allied eye health professionals with an interest in eye diseases around the globe. The first two volumes in the series described the state of the art in genetic eye research in Asia and the Pacific while the third focused on progress in Europe and the United States

Describes basic research of potential therapeutic importance Covers new drug therapy, gene therapy, cell therapy, tissue replacement, and artificial retina/cornea Describes application of AI in translational eye research

GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com